source
- Life insurers deem active-surveillance prostate cancer 'untreated' and deny term coverage, says patientHoward Wolinsky, a medical journalist, recounts that after his term life policy expired, eight insurers rejected his application because they considered his prostate cancer, managed by active surve…
- AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trialA Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in…